A FAAH better thing for cannabis users

"This exciting study sheds new light on cannabis dependence," said John Krystal, Editor of Biological Psychiatry. The study provides clues that may help develop treatments for cannabis use disorder for which none currently exist, due in part to our poor understanding of how cannabis affects brain systems.

In the study, first author Isabelle Boileau and colleagues from the Centre for Addiction and Mental Health in Toronto, Canada used a new positron emission tomography radiotracer, [11C]CURB, to measure FAAH levels in 10 active cannabis users, who had been using cannabis for an average of 18 years but were on recent withdrawal for the study, and 22 control subjects. They also analyzed blood, urine, and hair samples for traces of cannabinoids.

FAAH levels were reduced by 14-20% in chronic cannabis users compared with people who did not use cannabis. The low FAAH levels were associated with higher levels of cannabinoids in blood and urine, suggesting FAAH levels correlate with chronic and recent cannabis use.

Cannabis produces its key effects by stimulating CB1 cannabinoid receptors, the target of endocannabinoids. Together the data of the new study suggest that among chronic users, the enhanced stimulation of CB1 receptors by cannabis ingestion, which is known to downregulate CB1 receptors could, during acute cessation, lead to a suppression of FAAH activity in an attempt to restore "normal" CB1 stimulation by endogenous cannabinoids.

According to Krystal, the findings raise the possibility that normalizing cannabinoid CB1 receptor activity might play a role in reducing cannabis use and problems with impulse control in users.

The finding that heavy almost-daily cannabis use downregulates levels of FAAH after overnight cessation from cannabis use may explain the relative absence of withdrawal symptoms in very early abstinence, says Boileau, "and suggests that strategies aimed at keeping levels of this enzyme down might help reduce cannabis withdrawal symptoms."